EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The basis of complications in the context of SARS-CoV-2 infection: Pathological activation of ADAM17

Shenghai Jiang, Hao Yang, Zhongming Sun, Yi Zhang, Yan Li, Jida Li

Biochemical and Biophysical Research Communications · 2023

DOI: 10.1016/j.bbrc.2023.08.063 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Shenghai Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Zunyi Medical University Guizhou, China. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 139 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The virulence of SARS-CoV-2 decreases with increasing infectivity, the primary approaches for antiviral treatments will be preventing or minimizing the complications resulting from virus infection. ADAM metallopeptidase domain 17 (ADAM17) activation by SARS-CoV-2 infection has a dual effect on the development of the disease: increased release of inflammatory cytokines and dysregulation of Angiotensin converting enzyme II (ACE2) on cell surfaces, inflammatory cytokine infiltration and loss of ACE2 protective function lead to a significant increase in the incidence of related complications. Importantly, pathologically activated ADAM17 showed superior features than S protein in regulating ACE2 expression and participating in the intra cellular replication of SARS-CoV-2. In short, SARS-CoV-2 elicits only a limited immune response when it promotes its own replication and pathogenicity through ADAM17. Therefore, the pathological activation of ADAM17 may also represent a diminished innate antiviral defense and an altered strategy of SARS-CoV-2 infection. In this review, we summarized recent advances in our understanding of the pathophysiology of ADAM17, with a focus on the new findings that SARS-CoV-2 affects ADAM17 expression through Furin protein converting enzyme and Mitogen-activated protein kinase (MAPK) pathway, and raises the hypothesis that SARS-CoV-2 may mediates the pathological activation of ADAM17 by hijacking the actin regulatory pathway, and discussed the underlying biological principles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2Peptidyl-Dipeptidase AAngiotensin-Converting Enzyme 2Antiviral AgentsADAM17 Protein

Stichwörter der Autor:innen

ACE2ADAM17CytoskeletonFurinMAPKSARS-CoV-2

Substanzen

Peptidyl-Dipeptidase AAngiotensin-Converting Enzyme 2Antiviral AgentsADAM17 ProteinADAM17 protein, human

Autor:innen und Institutionen

  • Zunyi Medical University Guizhou, China.
  • Zunyi Medical University Guizhou, China; Key Laboratory of Maternal & Child Health and Exposure Science of Guizhou Higher Education Institutes, Zunyi, Guizhou, China. Electronic address: lijida198485@163.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Jiang, S., Yang, H., Sun, Z., Zhang, Y., Li, Y., & Li, J. (2023). The basis of complications in the context of SARS-CoV-2 infection: Pathological activation of ADAM17. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.08.063

Vancouver

Jiang S, Yang H, Sun Z, Zhang Y, Li Y, Li J. The basis of complications in the context of SARS-CoV-2 infection: Pathological activation of ADAM17. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.08.063

BibTeX
@article{Jiang2023,
  author = {Jiang, Shenghai and Yang, Hao and Sun, Zhongming and Zhang, Yi and Li, Yan and Li, Jida},
  title = {The basis of complications in the context of SARS-CoV-2 infection: Pathological activation of ADAM17},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  doi = {10.1016/j.bbrc.2023.08.063}
}
Kostenlos starten →